PROTHENA CORP PUBLIC LTD CO (PRTA) 8-K Current Report: February 27, 2026
Filed: February 27, 2026
Health Care
Pharmaceutical PreparationsPROTHENA CORP PUBLIC LTD CO (PRTA) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
PROTHENA CORP PUBLIC LTD CO 8-K Feb 27, 2026 Event Analysis
Item 7.01 · Regulation FD Disclosure
- • Share repurchase program authorized up to $100.0M of outstanding ordinary shares (par value $0.01/share)
- • Buyback signals management confidence in valuation at current price levels — typically bullish signal for existing shareholders
- • Program size relative to market cap determines materiality; investors should monitor execution pace and funding source
Item 8.01 · Other Events
- • Share repurchase plan authorized up to $100M of ordinary shares ($0.01 par value), expiring Dec 31, 2026
- • Plan is discretionary — no obligation to repurchase any shares, can be suspended or discontinued at any time
- • Buyback signals management confidence in share value; reduces share count if executed, potentially boosting EPS
Get deeper insights on PROTHENA CORP PUBLIC LTD CO
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.